Managed virological reaction after treatment with daclatasvir/pegylated interferon and ribavirin as a component of a clinical trial in a cirrhotic human immunodeficiency infection

William Grant caine; Balogun V. Ayo; Funmilayo Odukoya

Managed virological reaction after treatment with daclatasvir/pegylated interferon and ribavirin as a component of a clinical trial in a cirrhotic human immunodeficiency infection

Abstract

*William Grant caine, Balogun V. Ayo and Funmilayo Odukoya

This study presents a case of a sustained virological response to 24 weeks early cessation of hepatitis C direct acting antiviral (DAA) treatment with daclatasvir/peginterferon (PEG-IFN)/ribavirin (RBV), mandated by liver decompensation, in a clinical trial subject with advanced liver disease and human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection.

PDF

Share this article

Aims & Scope Abstracting and Indexing Submit Paper

Awards Nomination

Select your language of interest to view the total content in your interested language

Indexed In

Index Copernicus
Google Scholar
Sherpa Romeo
Open J Gate
Genamics JournalSeek
Academic Keys
CiteFactor
Electronic Journals Library
OCLC- WorldCat
Chemical Abstract Services (USA)
Academic Resource Index